Following the successful US launch of Nextida GC, Rousselot is debuting the ingredient to the European market at Vitafoods Europe 2025.
Nextida GC, the first ingredient from Rousselot’s Nextida platform of specific collagen compositions, is designed to maintain balanced glucose levels post-meal in healthy individuals by leveraging the body’s natural GLP-1 response.
In pre-clinical and clinical studies, Nextida GC has demonstrated the capacity to enhance the body's glucose regulation mechanism — which is important to avoid destabilising sugar crashes.
By reducing the prevalence of sugar crashes, users can avoid the potential associated consequences of this phenomenon, which as cravings, overeating and fatigue; which may all lead to subsequent weight gain.
“As consumer awareness of glucose management and GLP-11 increases, we are excited to present Nextida GC with new clinical data in Barcelona,” said Florencia Moreno Torres, Global Business Development Manager for Health & Nutrition at Rousselot.
“Nextida GC offers a unique approach in the nutraceutical space to help brands address the evolving metabolic health market, the natural way.”
Visitors at Rousselot booth will have an opportunity to taste Nextida GC application prototypes and gather first-hand insights in two expert-led sessions at the New Ingredients Theatre (3G266):
Beyond its glucose control solutions, Rousselot will present its collagen portfolio, including Peptan for beauty from within, mobility, sports recovery and sleep, and Colartix for joint care.
To be among the first in Europe to explore Nextida GC, and to discover the wider collagen and gelatin portfolio, visit booth 3K119.